---
schema_version: "secwatch.filing_event.v1"
accession: "0001490978-24-000045"
form_type: "8-K"
ticker: "SDGR"
cik: "0001490978"
company_name: "Schrodinger, Inc."
filed_at: "2024-05-01T23:59:59+00:00"
generated_at: "2026-06-03T02:41:55.958413+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Schrödinger Q1 revenue $36.6M, net loss $54.7M; FDA clears IND for SGR-3515

## Summary
- Total revenue $36.6M (down 44% YoY); software revenue $33.4M (+3.7%).
- Net loss $54.7M vs net income $129.1M in Q1 2023; non-GAAP net loss $62.4M.
- FDA cleared IND for SGR-3515 (Wee1/Myt1 inhibitor); Phase 1 solid tumors trial expected Q3 2024.
- SGR-1505 and SGR-2921 Phase 1 data readouts expected late 2024 or 2025.
- Rights to SOS1 inhibitor reverted from BMS after portfolio prioritization.

## SEC filing metadata
- accession: 0001490978-24-000045
- form_type: 8-K
- ticker: SDGR
- cik: 0001490978
- company_name: Schrodinger, Inc.
- filed_at: 2024-05-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1490978/000149097824000045/0001490978-24-000045-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1490978/000149097824000045/sdgr-20240501.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001490978-24-000045
- JSON: https://secwatch.observer/filing/0001490978-24-000045.json
- Plain text: https://secwatch.observer/filing/0001490978-24-000045.txt

## Key facts
- Earnings Releases
  Schrodinger, Inc. reported first quarter ended March 31, 2024 results: revenue $36.6 million, net income $(54.7) million. Guidance reaffirmed.
  - Period: first quarter ended March 31, 2024
  - Revenue: $36.6 million
  - Net income: $(54.7) million
  - Guidance: reaffirmed
  - Result: reported results
  source text: expressly incorporated by specific reference in such filing. --- EX-99.1 (EX-99.1) --- Schrödinger Reports First Quarter 2024 Financial Results First Quarter Total Revenue of $36.6 Million, Software Revenue of $33.4 Million Announces FDA Clearance of Investigational New Drug Application for SGR-3515, a Novel Wee1/Myt1 Inhibitor SGR-1505 and SGR-2921 on Track for
  evidence_url: https://www.sec.gov/Archives/edgar/data/1490978/000149097824000045/0001490978-24-000045-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.